Brefeldin A Ester Derivatives for Solubility and Half-Life Improvement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Brefeldin A (BFA) is limited by low bioavailability, poor water solubility, short plasma half-life, and high toxicity, making it unsuitable for clinical applications.
Innovation Solution
Development of a new class of BFA ester derivatives with improved pharmacokinetic properties, high solubility, and good safety for the prevention or treatment of hyperproliferative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Brefeldin A is used directly, then tumor proliferation inhibition activity is achieved, but bioavailability is low and water solubility is poor
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of Brefeldin A through esterification at different positions (C-4, C-6, C-7, C-11, C-12) with various alcohol groups. This structural modification changes the physical and chemical parameters of the molecule, resulting in derivatives with improved water solubility and bioavailability while maintaining the core macrolide structure responsible for anti-tumor activity
Solution Approach 2:
The patent creates composite chemical structures by combining the Brefeldin A core molecule with different ester groups. These composite derivatives integrate the anti-tumor properties of BFA with the solubility-enhancing characteristics of various ester moieties, achieving a balance between efficacy and pharmacokinetic properties
2Reliability
If Brefeldin A is used directly, then tumor proliferation inhibition activity is achieved, but plasma half-life is short and toxicity is high
Solution Approach 1:
The patent modifies the plasma half-life parameter by introducing ester groups with different chain lengths and structures. These modifications alter the metabolic stability and clearance rate of the compound, extending its duration of action in plasma while maintaining therapeutic efficacy
Solution Approach 2:
The ester groups act as intermediary structures that modulate the interaction between Brefeldin A and biological systems. These intermediaries protect the core molecule from rapid metabolism and clearance, thereby extending plasma half-life and reducing the frequency of administration required
3Reliability
If Brefeldin A is used directly, then tumor proliferation inhibition activity is achieved, but toxicity is high
Solution Approach 1:
The patent applies local quality by introducing ester groups at specific positions on the Brefeldin A molecule. This localized modification allows the drug to maintain its anti-tumor activity at the target site while reducing systemic toxicity through altered pharmacokinetic properties and selective activation
Solution Approach 2:
The patent converts the potentially harmful polyhydroxyl structure of Brefeldin A into beneficial ester derivatives. By esterifying the hydroxyl groups, the patent reduces the compound's reactivity and toxicity while maintaining its ability to inhibit tumor proliferation, effectively transforming a harmful characteristic into a beneficial one
Data Source
AI summary
The ester derivatives of brefeldin A represented by Formula (I) in the inhibition of tumor proliferation. The compounds are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Bart's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer and colorectal cancer, and have the potential to be developed as antitumor agents.